- Bioxytran (OTCQB: BIXT) secures a GMP quality source of camel hemoglobin through a $10 million joint venture with the Heme Foundation.
- This agreement is pivotal for developing a Universal Oxygen Carrier (UOC) with advantageous camel hemoglobin properties.
- The partnership aims to boost innovation in oxygen transport technology, enhancing Bioxytran's BXT-25 drug development potential.
Bioxytran, Inc. (OTCQB: BIXT), a key player in biotechnology, has successfully secured a source of GMP quality camel hemoglobin by forming a $10 million joint venture with the Heme Foundation. This partnership is a strategic move towards developing a Universal Oxygen Carrier (UOC), a project that leverages the unique properties of camel hemoglobin, which include superior stability, resilience, and a higher concentration than cow hemoglobin.
The secured hemoglobin will be crucial in enhancing Bioxytran’s leading oxygen transport molecule, BXT-25, which addresses conditions such as stroke, dementia, Traumatic Brain Injury (TBI), and Alzheimer's Disease. The absence of the risk of mad cow disease, along with the higher stability and resilience of camel hemoglobin under extreme conditions, underscores its value in the development of UOC.
The joint venture grants Bioxytran full intellectual property rights for UOC development, potentially unlocking millions in research advancements. This milestone agreement is expected to foster non-dilutive funding opportunities, further supporting Bioxytran's innovation in oxygen transport technology.
David Platt, CEO of Bioxytran, emphasized the importance of this agreement in strengthening their collaboration with the Heme Foundation and advancing their long-term strategy for the BXT-25 drug. He highlighted that the relationship with the Heme Foundation, combined with the advantageous properties of camel hemoglobin, positions Bioxytran to accelerate progress in their groundbreaking oxygen transport initiatives.
